Literature DB >> 2613606

The effect of new broad-spectrum antibiotics on faecal flora of cancer patients.

G J Meijer-Severs1, J H Joshi.   

Abstract

The effects of newly available broad-spectrum antibiotics, used for infection prophylaxis and therapy in cancer patients, on faecal aerobic and anaerobic bacteria were investigated. Quantitative and qualitative aerobic and anaerobic cultures were performed in 34 patients before therapy and between the sixth and eleventh day of therapy. Of the two prophylactic regimens norfloxacin plus amphotericin-B eliminated Enterobacteriaceae and enterococci without encouraging growth of yeasts or Clostridium difficile whereas trimethoprim-sulphamethoxazole did not eliminate enterococci and colonization with toxin producing C. difficile occurred in two of ten patients. The effect of the two infection prophylaxis regimens on counts of faecal anaerobes was comparable. Monotherapy with ceftazidime and combination therapy with ceftazidime plus tobramycin did not result in major changes (greater than or equal to 3 log increase or decrease) in faecal anaerobic bacteria. Enterobacteriaceae were eliminated except in one patient treated with ceftazidime. The effect of these therapeutic regimens on enterococci was variable. Colonization by yeasts or by toxin negative C. difficile (two of three patients) were found in the ceftazidime group only. During combination therapy with piperacillin plus amikacin for fever during granulocytopenia signs of a disturbed faecal flora were found in one of three patients. Changes in faecal anaerobic bacteria were most marked in the ceftazidime plus piperacillin group. Moreover the isolation of a toxin positive C. difficile occurred in this group, in a patient who was colonized with toxin negative C. difficile before treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2613606     DOI: 10.1093/jac/24.4.605

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Effects of ceftriaxone on faecal flora: analysis by micromorphometry.

Authors:  B C Meijer; G J Kootstra; D G Geertsma; M H Wilkinson
Journal:  Epidemiol Infect       Date:  1991-06       Impact factor: 2.451

2.  Characterization of human faecal flora by means of an improved fluoro-morphometrical method.

Authors:  G J Jansen; M H Wilkinson; B Deddens; D van der Waaij
Journal:  Epidemiol Infect       Date:  1993-10       Impact factor: 2.451

3.  The in vitro inactivation of thirteen beta-lactam antibiotics by other mechanisms than adsorption to faecal substance.

Authors:  H de Vries-Hospers; G Jansen; R Tonk; D Oenema; D van der Waaij
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

4.  Effects of broad-spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice.

Authors:  G Samonis; E J Anaissie; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

5.  The effect of FCE 22891, a new oral penem, on faecal flora anaerobes and their fermentation end products in patients with chronic obstructive pulmonary disease.

Authors:  G J Meijer-Severs; E van Santen; S M Puister; W G Boersma
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

6.  Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans.

Authors:  G Samonis; A Gikas; E J Anaissie; G Vrenzos; S Maraki; Y Tselentis; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

7.  Antibiotic-induced gut metabolome and microbiome alterations increase the susceptibility to Candida albicans colonization in the gastrointestinal tract.

Authors:  Daniel Gutierrez; Anthony Weinstock; Vijay C Antharam; Haiwei Gu; Paniz Jasbi; Xiaojian Shi; Blake Dirks; Rosa Krajmalnik-Brown; Juan Maldonado; Jack Guinan; Shankar Thangamani
Journal:  FEMS Microbiol Ecol       Date:  2020-01-01       Impact factor: 4.194

Review 8.  Host impairments in patients with neoplastic diseases.

Authors:  J Peter Donnelly; Nicole M A Blijlevens; Walter J F M van der Velden
Journal:  Cancer Treat Res       Date:  2014
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.